Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.

Hepatology international - 1 Mar 2018

Okubo Tomomi, Atsukawa Masanori, Tsubota Akihito, Toyoda Hidenori, Shimada Noritomo, Abe Hiroshi, Kato Keizo, Hayama Korenobu, Arai Taeang, Nakagawa-Iwashita Ai, Itokawa Norio, Kondo Chisa, Kawamoto Chiaki, Iio Etsuko, Tanaka Yasuhito, Kumada Takashi, Iwakiri Katsuhiko

Abstract excerpt

BACKGROUND/AIM: To evaluate the efficacy and safety of ledipasvir and sofosbuvir therapy for genotype 1b in chronic hepatitis C patients with chronic kidney disease (CKD) stage 3. METHODS: In a multicenter collaborative retrospective study, 706 patients who have received ledipasvir which is NS5A inhibitor, and sofosbuvir 400 mg which is NS5B nucleoside polymerase inhibitor daily for 12 weeks between September...

Topics

Join the communities discussing this publication.

Benzimidazoles
Creatinine
Fluorenes
Glomerular Filtration Rate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Renal Insufficiency, Chronic

Sustained Virologic Response

Uridine Monophosphate

Source

Identifiers

PMID: 29600429
DOI: 10.1007/s12072-018-9859-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.PMID 29600429Read ↗

Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.Semantic proximity Read ↗

Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.Semantic proximity Read ↗

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.Semantic proximity Read ↗

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.Semantic proximity Read ↗

Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.Semantic proximity Read ↗

Real-Life Data on Sofosbuvir/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience.Semantic proximity Read ↗

Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.Semantic proximity Read ↗

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.Semantic proximity Read ↗

Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and compensated cirrhosisSemantic proximity Read ↗

Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.Semantic proximity Read ↗

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.